Myeloma Crowd Invites Patients to Join Study Investigating Link Between Psoriasis and Myeloma
The Myeloma Crowd is inviting multiple myeloma patients with psoriasis to join a new study to uncover possible correlations between the two…
Myeloma
New MMRF Patient Registry Aims to Help Develop Personalized Treatments for Multiple Myeloma
Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with…
Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports
Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst…
Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma
IASO Biotherapeutics and Innovent Biologics are preparing the launch of a Phase 1b/2 clinical trial in China to evaluate the companies’ novel CAR…
Aplidin Prolongs Survival and Time to Disease Progression in Heavily Treated Multiple Myeloma Patients, Phase 3 Trial Shows
Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with…
Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new…
FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid…
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed…
Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma
Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with…
MMRF Launches CureCloud Data Hub to Identify Treatment Targets
Addressing the need for shared, comprehensive data to identify targets and provide personalized treatment road maps, the Multiple Myeloma Research Foundation (MMRF) is…
